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the theoretical framework to guide the focus group discussions. Each session was 
audio-recorded, transcribed, and participant responses were analyzed for qualita-
tive content. Results: Two, 60 minute focus groups (Total N= 12) were conducted. 
Time constraints and privacy issues presented as major themes in the discussions. 
Regarding advantages/disadvantages, participants emphasized the importance of 
counseling for the discussion of potential drug interactions and side effects of their 
medications and felt that their doctor would approve of them speaking with a 
pharmacist about their medications. However, both patient and pharmacist’ time 
constraints presented as a barrier to counseling. The majority of participants also 
stated that they would receive counseling more readily if it were provided in a 
more private environment. Only one participant was aware of MTM services and 
medication counseling requirements by law, however the majority stated that if they 
were aware of this mandate they would more readily accept pharmacist provided 
counseling. ConClusions: The identification of barriers to pharmacist provided 
counseling, specifically privacy and time limitations, may be beneficial for creating 
specific interventions that would increase patients’ intentions to receive pharmacist 
provided counseling.
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objeCtives: Describe the state of CER, its use and impact on medical decision-mak-
ing, and perceptions about the future for CER, application of evidence, and impact 
of CER Methods: Internet and mail survey of health care stakeholders, including 
government, health plans, researchers, human resources specialists, employers, and 
trade organizations, that are influential in or affected by CER; telephone follow-up 
to maximize response. Results: The 2014 survey, the fourth in a series begun in 
2010, found that health care stakeholders recognize the importance of CER but con-
tinue to believe, as in previous surveys, that significant impact of CER on treatment 
decisions is still in the future. PCORI is now recognized by most stakeholders as a 
leading organization in establishing research priorities, funding and monitoring 
research, and translating and disseminating the research. The 2014 survey indicates 
a clear need for more and better evidence. Only five percent of respondents believe 
the evidence base is sufficient to inform treatment decisions, and just 10 percent 
indicate that real-world evidence is being used to support decision-making. About 
15 percent of stakeholders indicated that variability in individual patient treatment 
response in being widely considered in treatment decisions. ConClusions: The 
2014 survey indicates continued belief among stakeholders that CER is important 
to them, but the most significant impacts are yet to be felt. The environment for 
CER is changing, and PCORI is recognized as a key organization in the spectrum of 
activities related to CER. The evidence base is not sufficiently complete to inform 
treatment decisions, and the influence of real-world evidence and variability in 
patient response are not yet apparent and warrant monitoring.
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objeCtives: We assessed the prevalence of shortages of drugs approved for orphan 
indications and evaluated the characteristics of the orphan drugs reported in short 
supply in the US. Methods: Orphan approval data were collected from the US FDA 
webpage. Shortage data were provided by the Drug Information Service, University 
of Utah Hospitals and Clinics (UU). The prevalence of shortages was estimated as 
a percentage of the total number of orphan indications approved in the US as of 
September 25, 2013. Results: The FDA approved 449 orphan indications for 338 
products (66.0% molecular entities, 23.7% therapeutic biologics, and 10.4% other 
biologics). Injectable products represented 59.7%, oral products 30.7% and other 
9.6% of the orphan indications. The average number of orphan indications per year 
increased from 6.9 in 1983-1989 to 23.3 in 2010-2013. The UU listed 1,740 shortages 
in the period 2000-09/25/2013. A total of 146 (8.4%) of shortages were for products 
with orphan indications. Shortages were estimated to affect 28.5% of FDA approved 
orphan indications (128 shortages out of 449 orphan indications approved by the 
FDA), this included 36.0% of indications for molecular entities, 15.8% of for thera-
peutic biologics, and 6.7% for biologics. The average estimated duration of shortages 
was 252.1±322.1 days for drugs with orphan indications and 270.3±336.3 days for 
other drugs (differences not statistically significant). The reason for the shortage was 
unknown for 50.2% of the shortages. Drugs with orphan indications were signifi-
cantly more likely to have manufacturing problems as the reason for the shortage 
(67.6%) than other drugs (52.9%, p= 0.02). ConClusions: Over one-fourth of the 
drugs with approved orphan indications were reported in short supply in the US. 
Problems with manufacturing represented most of the reported causes of shortages. 
Additional research is needed to assess the risk factors, causes and clinical impact 
of orphan drug shortages.
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highest for PILs (p< 0.001). Interaction analyses revealed that for one-page formats; 
the information load reduces, information anxiety reduces and product knowledge 
increases to a greater extent in high involvement scenario. ConClusions: The 
PILs had significantly higher patient comprehension as compared to the current 
practice and text-only prototypes. Increasing involvement further improves product 
knowledge, intention to read and attitude towards leaflet. The FDA could consider 
these findings and provide guidelines to design a concise prescription drug infor-
mation leaflet to eventually improve the expected outcomes associated with these 
information sources.
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objeCtives: This study aims to evaluate safety culture dimensions among phar-
macists using Hospital Survey on Patient Safety Culture (HSOPSC) developed by 
AHRQ. Methods: We surveyed nationwide the situation of patient safety culture 
in 37 hospitals (18,960 persons) between 2011 and 2012FY, which were allowed 
for additional costs on patient safety countermeasures under the social insurance 
medical fee schedule in Japan. Results: We classified 37 hospitals into three groups 
by number of beds; A group’s bed number was 20 to 200 (six hospitals), B group’s was 
201 to 400 (twelve hospitals), and C group’s was more than 401 (19 hospitals). The 
overall response rate was 87.9% (16,670/18,960 persons). Number of respondents 
in A group was 996 (1,116 persons; response rate: 89.2%) including 19 pharmacists, 
number of respondents in B group was 3,319 (3,674 persons; response rate: 90.3%) 
including 100 pharmacists, and number of respondents in C group was 12,355 (14,170 
persons; response rate: 87.2%) including 340 pharmacists. The overall average posi-
tive response rate (RR) for the 12 patient safety dimensions of the HSOPSC was 
46.6% in A group, 52.7% in B group and 51.0% in C group. In terms of occupational 
categories, RRs for pharmacists were 48.3% in A, 56.8% in B and 50.0% in C, RRs for 
physicians were 44.3% in A, 52.9% in B and 50.7% in C, and RRs for nurses were 43.4% 
in A, 52.8% in B and 51.6% in C, in each. RR for pharmacists was the highest among 
these three professionals in A and B groups. In terms of pharmacists, RRs in B group 
was the highest among three groups. ConClusions: The HSOPSC measurement 
provides the evidence for assessment of patient safety culture for pharmacists in 
Japan’s hospitals. This result suggested that pharmacists might be highly concerned 
with patient safety in Japan.
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objeCtives: Spontaneous reporting of adverse drug events (ADEs) by pharmacists 
helps ensure safe medication use; an important aspect of pharmaceutical care. This 
systematic review summarizes published survey articles regarding determinants 
of ADE reporting by pharmacists Methods: A literature search was conducted to 
identify original survey articles regarding pharmacists’ knowledge, attitudes and 
demographic factors associated with frequency of ADE reporting. Search engines 
used included PubMed, CINHAL and Web of Science.For each survey article, the 
following data were extracted: pharmacists working setting, sample size, survey 
delivery, response rate, reporting rate, demographic factors, knowledge and atti-
tudes associated with reporting Results: Only 32 of the 820 articles identified 
met the study requirements. The number of respondents in the studies included 
in this review ranged from 20 to 643. Response rate ranged from 26.4% to 100%. Self 
– administered questionnaires were used in 47% (15/32) and 41% (13/32) surveyed 
both hospital and community pharmacists. A study of Canadian pharmacists found 
that 65% had reported an ADE, followed by 59% and 32% of pharmacists in the UK 
and the US respectively. Pharmacists were found to have favorable attitude toward 
reporting (7 studies).Years of work experience as pharmacist was associated with 
significantly increased ADE reporting in 2 studies. Pharmacists in hospital settings 
reported significantly more ADEs than pharmacists in community/retail settings 
(4 studies).Lack of knowledge of pharmacovigilance concepts, systems and/or the 
ADE reporting process were significant barriers to reporting among 72%; uncertainty 
that a specific drug is responsible for a particular ADE in 38%; and lack of time in 
34% of studies. The factor most frequently recommended to improve reporting was 
special training/education programs related to pharmacovigilance concepts and 
ADE reporting (16/32). ConClusions: To improve reporting of ADE by pharma-
cist, educational interventions to address gaps in knowledge and attitudes could 
be implemented within pharmacy curriculum or as part of continuing education.
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objeCtives: While pharmacist provided counseling has proven effective in posi-
tive patient drug outcomes, only between 40-67% of patients are receiving this 
service. As the pharmacy profession moves towards providing greater patient care 
services, patients’ intentions to receive pharmacist provided counseling are not 
well understood. The objectives were to elicit modal salient behavioral beliefs, 
normative referents and control beliefs of patients regarding receiving commu-
nity pharmacist’ provided counseling and determine the factors that influence 
intention to receive counseling (i.e. legal requirements and awareness of MTM 
services). Methods: Focus groups were conducted with a convenience sample of 
community-pharmacy patients in Houston, TX, using a semi-structured interview 
guide with 14 open-ended questions. The theory of planned behavior was used as 
